Login / Signup

Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.

M CabezónR MalinverniJ BargayB XicoyS MarcéA GarridoM TormoL ArenillasR CollJ BorrasM J JiménezM HoyosD ValcárcelL EscodaF Vall-LloveraA GarciaL L FontE RámilaM BuschbeckLurdes Zamoranull null
Published in: Clinical epigenetics (2021)
Our findings suggest that in a subset of specific CpGs, altered DNA methylation patterns at diagnosis may be useful as a biomarker for predicting AZA response and survival.
Keyphrases
  • acute myeloid leukemia
  • dna methylation
  • genome wide
  • gene expression
  • allogeneic hematopoietic stem cell transplantation
  • free survival
  • copy number
  • acute lymphoblastic leukemia